Oxford Biomedica Acquires Remaining 10% Stake in US Subsidiary

Oxford Biomedica has acquired the remaining 10% stake in its US subsidiary, OXB US, from Q32 Bio, bringing its ownership to 100%. OXB US was established in 2022 and has a 96,000 sq ft facility with lentiviral and AAV vector capabilities, supporting the development and manufacturing of cell and gene therapies. The acquisition aligns with OXB's global network expansion strategy.

Oxford Biomedica (OXB) has acquired the remaining 10% stake in its US subsidiary, OXB US, from Q32 Bio, bringing its ownership to 100%. The acquisition aligns with OXB's global network expansion strategy and supports long-term growth in the viral vector manufacturing market.

OXB US, originally established in Bedford, MA, in 2022, is an AAV manufacturing and innovation business. The facility spans 96,000 sq ft and offers lentiviral and AAV vector capabilities. It has been fully integrated into OXB’s global network and has supported the onboarding of multiple new programs in the US.

Dr. Frank Mathias, CEO of OXB, commented, "The progression to full ownership of our US business marks an important step for OXB. It strengthens our position in a key market and helps meet growing demand for high-quality vector manufacturing – a critical enabler of the expanding cell and gene therapy market."

The acquisition follows OXB’s previous announcement on 9 April 2025, where it disclosed plans to acquire the final 10% interest in OXB US from Q32. The stake was originally held by Homology Medicines, which merged with Q32 in 2024. The transfer of Q32’s 10% holding to OXB US Inc. means that OXB US LLC is now wholly owned by OXB.

OXB’s global network includes development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and Bedford, MA, US. This expansion provides clients with access to deep expertise across AAV and lentiviral-based therapies, supporting them from early-stage development through to commercialization.

References:
[1] https://oxb.com/oxb-completes-acquisition-of-remaining-stake-in-us-subsidiary/
[2] https://finance.yahoo.com/news/oxford-biomedica-completes-acquisition-remaining-170649102.html